These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 24129613)

  • 1. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
    Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
    Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
    Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
    Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESHRE guideline: ovarian stimulation for IVF/ICSI
    Ovarian Stimulation TEGGO; Bosch E; Broer S; Griesinger G; Grynberg M; Humaidan P; Kolibianakis E; Kunicki M; La Marca A; Lainas G; Le Clef N; Massin N; Mastenbroek S; Polyzos N; Sunkara SK; Timeva T; Töyli M; Urbancsek J; Vermeulen N; Broekmans F
    Hum Reprod Open; 2020; 2020(2):hoaa009. PubMed ID: 32395637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles.
    Vidal MDM; Martínez F; Rodríguez I; Polyzos NP
    Hum Reprod; 2024 May; 39(5):1098-1104. PubMed ID: 38498835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study.
    Koedooder R; Singer M; Schoenmakers S; Savelkoul PHM; Morré SA; de Jonge JD; Poort L; Cuypers WJSS; Beckers NGM; Broekmans FJM; Cohlen BJ; den Hartog JE; Fleischer K; Lambalk CB; Smeenk JMJS; Budding AE; Laven JSE
    Hum Reprod; 2019 Jun; 34(6):1042-1054. PubMed ID: 31119299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
    Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
    Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
    Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial.
    Cédrin-Durnerin I; Carton I; Massin N; Chevalier N; Dubourdieu S; Bstandig B; Michelson X; Goro S; Jung C; Guivarc'h-Lévêque A
    Hum Reprod; 2024 Sep; 39(9):1979-1986. PubMed ID: 39008826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
    Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
    Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome.
    de Wilde MA; Veltman-Verhulst SM; Goverde AJ; Lambalk CB; Laven JS; Franx A; Koster MP; Eijkemans MJ; Fauser BC
    Hum Reprod; 2014 Jun; 29(6):1327-36. PubMed ID: 24777850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
    Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
    Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.